The following article is part of coverage from the American Academy of Dermatology’s Annual Meeting (AAD 2020). Because of concerns regarding the coronavirus disease 2019 (COVID-19) pandemic, all AAD 2020 sessions and presentations were transitioned to a virtual format. While live events will not proceed as planned, readers can click here to view more news related to research presented during the AAD VMX 2020 virtual experience.


The number of baseline molluscum contagiosum (MC) lesions does not appear to affect the efficacy or safety associated with VP-102, a proprietary topical therapy that contains cantharidin (0.7% w/v), according to study results presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2020, held online from June 12 to 14, 2020.

Findings were according to pooled results of 2 phase 3 multicenter, randomized trials. Patients ≥2 years of age with MC were enrolled in the trials, both of which randomly assigned participants to either topical administration of VP-102 or vehicle. Study treatment and vehicle control were applied to all baseline and new lesions once every 21 days until clear with a maximum of 4 applications. Assessors blinded to treatment allocation recorded lesion counts at days 21, 42, 64, and 84 (end of study visit). Adverse events (AEs), particularly local site reactions, were monitored throughout the study.

The analyses stratified VP-102-treated patients into quartiles by baseline lesion count. Quartile 1 included patients with 1 to 7 lesions (n=92), quartile 2 included patients with 8 to 14 lesions (n=82), quartile 3 included patients with 15 to 28 lesions (n=67), and quartile 4 included patients with ≥29 lesions (n=68). Treatment with VP-102 across all quartiles was associated with significantly higher clearance rates for all baseline and new lesions compared with vehicle control (P <.05). Similar complete clearance rates were observed for all VP-102 quartiles, ranging from 43.3% for quartile 3 to 63% for quartile 1.


Continue Reading

According to the researchers, the VP-102 groups with the fewest lesions reported significantly higher percentages of complete lesion clearance compared with the vehicle group (P <.05) in an analysis of the percentage of patient with complete lesions clearance by time point. Application site vesicles, pain, erythema, and pruritus were the most common AEs, all of which were similar in occurrence across groups.

Disclosure: This clinical trial was supported by Verrica Pharmaceuticals. Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.

Visit our conference section for more coverage from AAD VMX 2020.


Reference

Olivadoti M, Kwong P, Gonzales M, et al. Safety and efficacy of VP-102 in molluscum contagiosum (MC) by lesion count quartile: Pooled results of two phase 3 multicenter, randomized, vehicle-controlled trials for the topical treatment of MC. Presented at: AAD VMX 2020; June 12-14, 2020. Abstract/Poster 13772.

This article originally appeared on Dermatology Advisor